Condition: Non-small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Central Alabama Research ( Site 0108) | Birmingham, Alabama, United States | Recruiting |
| University of Connecticut Health Center ( Site 0130) | Farmington, Connecticut, United States | Recruiting |
| Stamford Hospital ( Site 0126) | Stamford, Connecticut, United States | Recruiting |
| Mount Sinai Cancer Center ( Site 0137) | Miami Beach, Florida, United States | Completed |
| Indiana University Health Arnett Cancer Center ( Site 0116) | Lafayette, Indiana, United States | Recruiting |
| New England Cancer Specialists ( Site 0139) | Westbrook, Maine, United States | Recruiting |
| New York Oncology Hematology, P.C. ( Site 0119) | Albany, New York, United States | Recruiting |
| St. Charles Health System, Inc ( Site 0146) | Bend, Oregon, United States | Recruiting |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111) | Lancaster, Pennsylvania, United States | Recruiting |
| Blue Ridge Cancer Care ( Site 0144) | Roanoke, Virginia, United States | Recruiting |
| Instituto Alexander Fleming ( Site 0311) | Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Instituto de Investigaciones Clinicas Mar del Plata ( Site 0300) | Mar del Plata, Buenos Aires, Argentina | Recruiting |
+ 183 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07190248